12:00 AM
 | 
May 28, 2002
 |  BioCentury  |  Product Development

Going for the insulin pill

GlaxoSmithKline plc has placed its bet in the non-injected insulin field, teaming up to develop and market Nobex Pharmaceuticals Inc.'s polymer conjugate technology to covalently modify proteins for oral delivery.

GSK has been building a diabetes portfolio on top of its Avandia rosiglitazone, which is approved as a monotherapy and in combination with metformin to treat insulin resistance in Type II diabetics. Last year, GSK received an approvable letter for Avandia plus insulin to treat Type II diabetes, and the pharma company has two beta3 adrenergic agonists in Phase I testing for Type II diabetes: GW427353 and SB418790.

Nobex has taken its lead oral insulin product, HIM2 (hexyl insulin monoconjugate-2), through Phase II testing in liquid and capsule formulations. The partners...

Read the full 605 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >